A small RCT says DHA during breastfeeding boosts infant brain development. A 16× larger trial disagrees.
A June 2026 Frontiers in Nutrition RCT (Gupta et al.; n=60) found that DHA supplementation during lactation significantly improved infant neurodevelopmental scores at 6 months. The far larger DHANI trial (n=957; 400 mg/day algal DHA) found no benefit at 12 months. The article breaks down both studies, explains the contradiction, and closes with a concrete recommendation: meet the 200–300 mg/day DHA threshold through fatty fish 2–3×/week or an algal supplement — but don't treat supplementation as a guaranteed developmental intervention.
A new Indian randomized trial published June 25, 2026 found that mothers who took DHA supplements while breastfeeding had infants with higher developmental scores at six months. The headline sounds clean. The underlying evidence base is not.
What the new study did
Gupta, Bains, and Aggarwal at Punjab Agricultural University recruited 60 healthy lactating mothers one month postpartum in Punjab, India and randomized them to four groups: urban control, urban supplemented, rural control, and rural supplemented — 15 participants per group. 1 Supplemented mothers received DHA capsules daily for 150 days. (The exact milligram dose is not disclosed in the currently available pre-typeset abstract; the formatted article is pending publication.)
The authors measured three sets of outcomes:
- Breast milk and blood DHA status: Both supplemented groups showed significantly higher erythrocyte DHA concentration and breast milk DHA concentration compared with controls (p < 0.001). 1
- Infant growth: Infants of supplemented mothers had higher weight, length, and head circumference at six months, along with more favorable weight-for-age, length-for-age, and weight-for-length Z-scores, and a lower prevalence of slow weight gain (p < 0.05). 1
- Infant neurodevelopment: Supplemented infants scored significantly higher on both the Motor Development Quotient and the Mental Development Quotient of the DASII (Developmental Assessment Scale for Indian Infants) at six months (p < 0.001). 1
Baseline dietary intake data showed that alpha-linolenic acid and DHA consumption were inadequate in both urban and rural populations, with rural mothers consuming significantly less (p < 0.001). The authors concluded that "maternal DHA supplementation during lactation was associated with improved maternal DHA status, enhanced breast milk DHA concentration, favorable infant growth indicators, and higher neurodevelopmental scores." 1
The contradicting evidence you need to see
The DHANI trial (Khandelwal et al., 2020, published in Nutrients) is the most directly comparable study in existence. It enrolled 957 pregnant and lactating Indian women — 16× the Gupta sample — and supplemented them with 400 mg/day algal DHA from mid-pregnancy through six months postpartum. 2 The primary outcome was offspring neurodevelopment at 12 months, measured with the same DASII instrument.
The result: no benefit. Development Quotient scores were 96.6 ± 12.2 in the DHA group versus 97.1 ± 13.0 in the placebo group (p = 0.60). 2 The DHANI team used a dose that exceeds current international recommendations, applied it across a demographically similar population, and used the same measurement tool. The null result was not a close call.
Loading chart…
| Feature | Gupta et al. 2026 | DHANI (Khandelwal et al. 2020) |
|---|---|---|
| n (analyzed) | 60 (15/group) | 957 |
| DHA dose | Undisclosed | 400 mg/day algal DHA |
| Timing | Lactation only (150 days) | Mid-pregnancy through 6 months postpartum |
| Neurodevelopment outcome | DASII Motor DQ + Mental DQ | DASII DQ |
| Assessment age | 6 months | 12 months |
| Neurodevelopment result | Significant improvement (p < 0.001) | No difference (DQ 96.6 vs 97.1, p = 0.60) |
| Country / population | Punjab, India (urban + rural) | Multiple sites, India |
Side-by-side, the scale difference between these two trials is the central methodological problem for interpreting the Gupta finding. 12
The InfantRisk Center at Texas Tech University Health Sciences Center, reviewing the broader DHA supplementation literature through 2020, reached a similar conclusion: "Current evidence is inconclusive, and ultimately does not support the use of DHA (i.e. fish oil) supplements during pregnancy for neurocognition in infants." 3 For term infants specifically, the review found that higher breast milk DHA from supplementation "does not seem to correlate with improvements in child visual or brain development."
These two bodies of evidence are not in agreement, and the Gupta study does not resolve the conflict.
Why the Gupta study can't settle the debate
Several structural limitations constrain how much weight this new RCT can carry:
- Sample size: n = 60 (15 per group) is substantially underpowered for developmental endpoints, which are inherently noisy. The DHANI trial was powered to detect a 5-point DQ difference with 80% confidence.
- No effect sizes in the abstract: Statistically significant p-values (p < 0.001, p < 0.05) tell you the direction of the effect, not its magnitude. Without mean DQ scores ± SD, the clinical meaningfulness of the neurodevelopmental finding cannot be assessed. The formatted article has not yet published.
- Unknown DHA dose: The exact daily DHA dose is not disclosed in the available abstract. This prevents any dietary translation — you cannot tell readers what dose to aim for based on this study alone.
- DASII measurement caveats: The DASII is validated for Indian infants aged 1–30 months, but Madaan et al. (2021) conducted a systematic review and found that DASII cutoff points are inconsistently applied across Indian studies over the past two decades. 4 This limits cross-study comparability even within the Indian research context.
- Assessment timing: Gupta measured DASII at six months; DHANI measured at 12 months. DHA's theorized neurodevelopmental window extends into the second year of life, meaning earlier scores may not predict later outcomes.
The authors themselves note that their study "suggests" an association — appropriately hedged language for an underpowered trial that contradicts a much larger one.
What the evidence does support: dietary DHA status for lactating women
The uncontested finding in this literature is that most lactating women consume far less DHA than recommended, and supplementation reliably raises both maternal blood DHA and breast milk DHA levels. That much is consistent across studies, including Gupta's new data and the DHANI follow-up analysis (Khandelwal et al., 2023) showing that breast milk DHA concentration rose significantly with supplementation in the DHANI cohort. 5
The question is whether that increase in breast milk DHA translates to better infant neurodevelopmental outcomes. The short answer from the current RCT literature: probably not reliably enough to bank on supplements as a neurodevelopment strategy for term infants in otherwise replete populations.
The current international consensus recommends lactating women consume at least 200 mg DHA per day (Koletzko et al., 2007 consensus); FAO/WHO recommends 300 mg/day during pregnancy. 3 Importantly, Stoutjesdijk et al. (2018) estimated that optimal breast milk DHA levels may require 535–715 mg DHA + EPA/day — considerably above the 200 mg floor. 3
Loading stats card…
Average American intake sits far below that range — most people consume roughly 4 oz of fish per week, against the recommended 8–12 oz. The gap between habitual intake and recommendation is where the practical action lives.
Study limitations
From Gupta et al. (2026):
- n = 15 per group; substantially underpowered for a neurodevelopmental primary endpoint
- Exact DHA dose withheld from the pre-typeset abstract — the critical dietary variable for translation
- DASII measured at 6 months; longer-term neurodevelopment not assessed
- No blinding described; no registered trial identifier identified in the abstract
- Directly contradicted by the DHANI trial (n = 957, same population, same instrument, p = 0.60 null result) 2
- Effect sizes (mean DQ scores, Z-score values, anthropometric means) not reported; clinical significance cannot be assessed from the abstract alone
Known DASII measurement limitation:
- Madaan et al. (2021) systematic review identified inconsistent cutoff point use across Indian DASII studies — cross-study score comparisons have limited reliability 4
The actionable recommendation
The Gupta study is an early signal from a small trial — it does not override the larger body of evidence, and its missing dose data prevent direct dietary translation. What can be translated is the consensus recommendation that most lactating women in both urban and rural settings consume inadequate DHA, and that dietary sources or supplementation reliably corrects that deficit.
For lactating women and the dietitians advising them:
- Aim for ≥ 200 mg DHA per day from food or supplements. The international consensus floor is 200 mg/day (Koletzko et al., 2007); FAO/WHO recommends 300 mg/day during pregnancy, a level that likely applies to lactation as well. 3 Dietary sources that reach this target: 100g of salmon delivers 1.2–2.5g DHA; 100g of sardines delivers 0.5–1.0g; 100g of mackerel delivers 0.7–1.4g.
- Treat fish intake as the first-line strategy. Eating fatty fish 2–3 times per week is both the most direct route to meeting the DHA target and consistent with general dietary guidance for lactating women. 3
- If supplementing, choose an algal-DHA product. Algal DHA (the form used in DHANI) avoids the methylmercury concerns associated with some fish oils and provides preformed DHA directly. A dose in the 200–400 mg/day range is supported by EFSA's approved health claim and the DHANI trial protocol. 2
- Do not supplement expecting a guaranteed neurodevelopmental boost for term infants. The current evidence — anchored by DHANI's null result at 400 mg/day — does not support DHA supplementation as a reliable neurodevelopment intervention for term infants in populations with access to adequate nutrition. The Gupta study is too small and too incomplete to shift that assessment. Maternal DHA status is still worth optimizing for the mother's own health and for correcting a widespread dietary shortfall.
- Watch for the formatted Gupta article. Once the full text publishes with the DHA dose and outcome tables, the study can be evaluated properly. If the reported effect sizes are large and dose is in a range distinct from DHANI's 400 mg/day, it may warrant a reassessment.
Cover image: AI-generated illustration
References
- 1Gupta, Bains & Aggarwal 2026, Frontiers in Nutrition
frontiersin.org
- 2Khandelwal et al. 2020 DHANI trial, Nutrients / PMC
pmc.ncbi.nlm.nih.gov
- 3Setterquist & Garner 2020, InfantRisk Center
infantrisk.com
- 4Madaan et al. 2021, Indian Journal of Pediatrics
pubmed.ncbi.nlm.nih.gov
- 5Khandelwal et al. 2023, Current Developments in Nutrition
pmc.ncbi.nlm.nih.gov
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.